Supplementary Material for: Safety and efficacy of asciminib in chronic myeloid leukemia patient with chronic kidney diseases: a case report

Chronic myeloid leukemia is characterized by the presence of the BCR::ABL1 fusion gene, and tyrosine kinase inhibitors have revolutionized its treatment. Asciminib, a targeted ABL inhibitor, offers a promising alternative for patients who do not respond to or tolerate two or more conventional tyrosine kinase inhibitors. However, limited data exist regarding its safety and efficacy in individuals with chronic kidney disease. We present a case report of a 62-year-old chronic myeloid leukemia patient with stage 3 chronic kidney disease who experienced TKI intolerance, primarily due to fluid retention. Transitioning to asciminib therapy not only resulted in a deep molecular response but also did not exacerbate renal function, and resolve the fluid retention issue.